What is Rosai-Dorfman disease?
Rosai-Dorfman disease (RDD) is a rare disorder of the immune system in which large immune cells called histiocytes build up in the body. It most often causes large, painless swollen lymph nodes in the neck, but it can also affect the skin, nose and sinuses, eyes, bones, brain and other organs.
The disease was described in detail by the pathologists Juan Rosai and Ronald Dorfman in 1969, under the name sinus histiocytosis with massive lymphadenopathy. The French pathologist Pierre-Paul Destombes had reported similar cases a few years earlier, so it is also called Rosai-Dorfman-Destombes disease (Foucar, Rosai and Dorfman, 1990; Abla et al., 2018).
RDD belongs to the same broad family as Langerhans cell histiocytosis and Erdheim-Chester disease. In the current classification of histiocytic disorders, it forms the “R group” (Abla et al., 2018).
For many people RDD is mild and may settle on its own. Others have disease in several organs that needs treatment. Research has shown that some cases carry gene changes in the MAPK signalling pathway, which means RDD can behave like a slow-growing neoplasm in some people (Garces et al., 2017).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of disease | Rare histiocytic disorder (R group histiocytosis) |
| How common | Very rare; around 100 new cases a year are estimated in the United States |
| Typical age | Mostly children and young adults, average about 20; can occur at any age |
| Main sites | Lymph nodes of the neck; skin, nose and sinuses, eye socket, bone, brain coverings |
| Key symptoms | Large painless neck lumps, fever, night sweats, tiredness |
| Gene changes | KRAS, NRAS, MAP2K1 and others in about a third of cases |
| Main treatment | Watchful waiting, surgery, steroids, sirolimus, chemotherapy or MEK inhibitors |
| Outlook | Usually good; a small number have serious, long-lasting disease |
2. Types of Rosai-Dorfman disease
| Type | Description |
|---|---|
| Classic (nodal) RDD | Large lymph nodes, usually in the neck, often with fever and raised inflammatory markers |
| Extranodal RDD | Disease outside the lymph nodes; occurs in about 4 in 10 people, sometimes with nodal disease |
| Cutaneous RDD | Limited to the skin; more common in adults of Asian origin |
| Central nervous system RDD | Masses on the coverings of the brain or spinal cord |
| Familial RDD | Linked with inherited changes, for example in SLC29A3 (H syndrome) |
| RDD with immune disease | Occurs with conditions such as autoimmune lymphoproliferative syndrome, lupus or IgG4-related disease |
| RDD with cancer | Occasionally found alongside lymphoma or other histiocytic disorders |
3. Causes and risk factors
The cause of RDD is not fully understood. It seems to arise from a mixture of immune system overactivity and, in some people, acquired gene changes in the histiocytes.
| Factor | Notes |
|---|---|
| MAPK pathway mutations | KRAS, NRAS, MAP2K1 or ARAF changes in about a third of cases (Garces et al., 2017) |
| Inherited gene changes | SLC29A3 (H syndrome) or FAS (autoimmune lymphoproliferative syndrome) in rare families |
| Autoimmune disease | Linked with some cases |
| Infections | Viruses have been suggested as triggers, but none has been proven |
| Age and background | More common in children and young adults; classic RDD is reported more often in males and in people of African descent |
RDD is not infectious and cannot be passed from person to person. Most cases are not inherited.
4. How does it look
Swollen lymph nodes
The most typical sign is large, firm, painless lymph nodes on both sides of the neck. The nodes can become very large and may be visible as bulky swellings that change the shape of the neck.
Skin
| Skin feature | Description |
|---|---|
| Papules and nodules | Firm, raised bumps, red-brown, yellow or skin-coloured |
| Plaques | Flat, thickened patches |
| Location | Face, trunk and limbs |
| Number | Single or many |
Eye and face
Disease in the eye socket can cause a bulging eye, swelling of the eyelid or a lump near the eye. Disease in the nose and sinuses can cause a swollen nose or a mass inside the nose.
On scans
| Scan | Possible findings |
|---|---|
| CT or ultrasound | Large lymph nodes in the neck and elsewhere |
| MRI of the brain | Masses on the brain covering (dura) that can look like meningiomas |
| Bone imaging | Areas of bone loss, often with a clear edge |
| PET-CT | Active areas of disease throughout the body |
Under the microscope
RDD has a very typical appearance (Abla et al., 2018; Bruce-Brand, Schneider and Schubert, 2020):
| Feature | Description |
|---|---|
| Large pale histiocytes | Big cells with abundant pale cytoplasm |
| Emperipolesis | Whole lymphocytes or plasma cells sitting inside the histiocytes, a key clue |
| Plasma cells | Often numerous around the histiocytes |
| Staining | Histiocytes are positive for S100, CD68, CD163 and OCT2; negative for CD1a and CD207 (unlike Langerhans cell histiocytosis) |
5. Symptoms
Symptoms depend on where the disease is.
Lymph node disease
- Large, painless lumps in the neck, often on both sides
- Swollen lymph nodes in the armpits, groin or chest
- Fever
- Night sweats
- Tiredness and weight loss
Disease in other organs
| Site | Possible symptoms |
|---|---|
| Skin | Bumps or patches that are usually painless |
| Nose and sinuses | Blocked nose, nosebleeds, change in the shape of the nose |
| Eye socket | Bulging eye, double vision, reduced vision |
| Brain or spinal cord | Headache, seizures, weakness, numbness or problems with balance |
| Bone | Bone pain or a fracture |
| Kidneys | Usually no symptoms early; sometimes kidney problems |
| Breathing passages | Cough, breathlessness or noisy breathing |
| Salivary glands | Swelling in front of the ear or under the jaw |
Laboratory findings
Blood tests often show anaemia, a raised ESR or CRP and high antibody levels (polyclonal hypergammaglobulinaemia).
When to seek medical advice
See a doctor if you have lumps in the neck that last more than a few weeks, particularly with fever, night sweats or weight loss.
Seek prompt help for seizures, sudden weakness, vision changes or breathing problems.
6. Diagnosis
| Test | Purpose |
|---|---|
| Biopsy | The key test; a lymph node or affected tissue is examined under the microscope |
| Immunohistochemistry | Confirms S100- and OCT2-positive, CD1a-negative histiocytes |
| IgG4 staining | Checks for overlap with IgG4-related disease |
| Molecular testing | Looks for KRAS, MAP2K1 and other gene changes |
| Blood tests | Blood count, ESR, CRP, antibodies, kidney and liver function |
| PET-CT or CT | Shows the extent of disease |
| MRI | For the brain, spine or eye socket when needed |
| Tests for associated conditions | Autoimmune disease, immune deficiency and lymphoma where relevant |
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Lymphoma | Abnormal lymphocytes rather than histiocytes |
| Infection, such as tuberculosis | Different tissue changes; organisms may be found |
| Langerhans cell histiocytosis | Histiocytes are CD1a- and CD207-positive |
| Erdheim-Chester disease | Mostly bone, kidney and heart disease in older adults; different cells |
| IgG4-related disease | Many IgG4 plasma cells; overlaps in some people |
| Meningioma | Brain RDD can look like a meningioma on MRI |
7. Treatment
Treatment is tailored to the sites involved, symptoms and risk to organs. International consensus recommendations guide care (Abla et al., 2018).
| Situation | Usual approach |
|---|---|
| Mild nodal or skin disease without symptoms | Watchful waiting; many cases improve or settle on their own |
| A single troublesome lesion | Surgical removal, which is often curative |
| Symptoms or organ involvement | Corticosteroids such as prednisone or dexamethasone |
| Disease that returns or does not respond | Low-dose chemotherapy such as methotrexate, cladribine or clofarabine |
| Disease with immune features | Sirolimus, rituximab or other immune treatments in selected cases |
| Disease with MAPK mutations or severe disease | MEK inhibitors such as cobimetinib (Diamond et al., 2019; Abeykoon et al., 2022) |
| Brain, eye or airway disease threatening function | Surgery, steroids or radiotherapy |
MEK inhibitors
Cobimetinib blocks the MAPK pathway that is overactive in many histiocytic disorders. In a study of histiocytic neoplasms, most patients responded, including those with RDD (Diamond et al., 2019).
In the United States, cobimetinib is approved for adults with histiocytic neoplasms. Responses have also been seen in RDD without a detectable mutation (Abeykoon et al., 2022).
Side effects of treatment
| Treatment | Possible side effects |
|---|---|
| Steroids | Weight gain, mood changes, raised blood sugar, bone thinning |
| Chemotherapy | Low blood counts, infections, tiredness |
| MEK inhibitors | Rash, diarrhoea, eye changes, muscle problems, heart effects |
| Surgery | Scarring and effects on nearby tissue |
Rosai-Dorfman disease in children
Children are among the people most often affected. In children, RDD usually causes large neck lymph nodes with fever, and the disease often settles over months without the need for strong treatment.
Children with RDD are checked carefully for associated conditions, such as autoimmune lymphoproliferative syndrome or inherited H syndrome. The latter causes skin hardening and darkening, hearing loss, heart problems and diabetes, alongside the histiocyte build-up.
Treatment choices in children aim to avoid long-term side effects. Steroids are often tried first, and low-dose chemotherapy or targeted drugs are reserved for disease that persists or threatens organs.
Practical points during treatment
| Topic | Advice |
|---|---|
| Steroid courses | Do not stop steroids suddenly; the dose is reduced gradually |
| Infections | Report fever promptly, especially while on chemotherapy or sirolimus |
| Skin care | Use sun protection and gentle moisturisers if on a MEK inhibitor |
| Eye checks | Regular eye examinations are recommended with MEK inhibitors |
| Vaccines | Ask before having live vaccines during treatment |
8. Outlook (prognosis)
The outlook is generally good. Many people have disease that improves on its own or responds to treatment.
| Situation | Outlook |
|---|---|
| Classic nodal RDD | Often settles over months to years; may come and go |
| Single skin or bone lesion | Usually excellent after removal |
| Brain or spinal cord disease | Can cause lasting problems; recurrences are possible |
| Kidney, liver or lower airway involvement | Linked with a more serious course |
| RDD with immune disease | Course may follow the underlying condition |
Death from RDD is uncommon. It has been reported in a small proportion of patients, mainly those with widespread disease, involvement of vital organs or associated immune problems (Foucar, Rosai and Dorfman, 1990).
9. Follow-up
RDD can come back years later, so regular follow-up is recommended:
- Clinical check-ups and examination of lymph nodes and skin
- Blood tests, including inflammatory markers
- Scans at intervals, or if new symptoms appear
- Eye and neurology reviews when relevant
10. Living with Rosai-Dorfman disease
- Keep a record of symptoms such as fever, sweats and new lumps
- Ask for a named specialist with experience of histiocytic disorders
- Ask about patient organisations, such as the Histiocytosis Association, for information and support
- Look after general health with good nutrition, rest and exercise
- Discuss side effects early, especially with steroids or MEK inhibitors
- Tell other doctors about your diagnosis before surgery or new medicines
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is Rosai-Dorfman disease cancer? | It is classed as a histiocytic disorder. Some cases carry gene changes like a slow-growing neoplasm, but most are not life-threatening |
| Can it go away without treatment? | Yes, many cases improve or resolve on their own |
| Is it inherited? | Usually not; rare familial forms exist |
| Is it contagious? | No |
| Can children get it? | Yes, children and young adults are most often affected |
| Will it come back? | It can recur, sometimes after many years, so follow-up is important |
More questions people ask
| Question | Answer |
|---|---|
| Why did it take so long to diagnose? | RDD is rare and can look like lymphoma, infection or other conditions, so several biopsies are sometimes needed |
| Can I work or go to school? | Most people can continue normal activities, with time off during intensive treatment |
| Will the lumps leave a mark? | Neck lumps usually shrink back fully when the disease settles; skin lesions may leave slight scarring or colour change |
| Does diet affect RDD? | No specific diet has been shown to help, but a balanced diet supports general health |
12. Questions to ask your care team
- Which organs are affected?
- Do I need treatment now, or can we watch and wait?
- Was a gene change found in my biopsy?
- Would a MEK inhibitor be an option for me?
- Is there an associated immune condition to look for?
- How often will I need scans and check-ups?
- Can you refer me to a histiocytosis specialist or clinical trial?
Resources
- Abeykoon, J.P. et al. (2022) ‘Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman disease based on KRAS and MEK alteration status’, JAMA Oncology, 8(12), pp. 1816-1820.
- Abla, O. et al. (2018) ‘Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease’, Blood, 131(26), pp. 2877-2890.
- Bruce-Brand, C., Schneider, J.W. and Schubert, P. (2020) ‘Rosai-Dorfman disease: an overview’, Journal of Clinical Pathology, 73(11), pp. 697-705.
- Diamond, E.L. et al. (2019) ‘Efficacy of MEK inhibition in patients with histiocytic neoplasms’, Nature, 567(7749), pp. 521-524.
- Foucar, E., Rosai, J. and Dorfman, R. (1990) ‘Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity’, Seminars in Diagnostic Pathology, 7(1), pp. 19-73.
- Garces, S. et al. (2017) ‘Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease’, Modern Pathology, 30(10), pp. 1367-1377.
- Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms’, Leukemia, 36(7), pp. 1703-1719.
- Papo, M. et al. (2019) ‘Systemic histiocytosis (Langerhans cell histiocytosis, Erdheim-Chester disease, Destombes-Rosai-Dorfman disease): from oncogenic mutations to inflammatory disorders’, Current Oncology Reports, 21(7), p. 62.
Prepared by the editorial team, October 2026.